Thread by @calyxlaw

Controlled release psilocybin + cannabinoid formulations?

New published patent application on multilayer tablets & capsules w psilocybe-derived + cannabis-derived compounds

Filed by Tassili Life Sciences, acquired last yr by Champignon Brands

patentscope.wipo.int/search/en/deta… $SHRM

1/

Application claims compositions of “psilocybe-derived agent and a cannabis-derived agent”

”formulated in multiple layers to release the psilocybin-derived agent and the cannabis-derived agent at multiple different times, dosages and/or locations in a subject during dosing”

2/

Application asserts controlled release formulations of psilocybin + CBD can result in “multiple chemical-induced high/low shocks”

"useful in eliciting short or long term traumatic experience suppression in similar fashion to electroshock therapy without memory eradication”

3/

Preliminary written opinion found psilocybe & cannabis derived compounds not disclosed before “in a tablet formulated in alternating layers,” & thus novel

However, “skilled person would not require inventive ingenuity to use the layered formulation”

patentscope.wipo.int/search/docs2/p…

4/

Preliminary written opinion cited two earlier-filed applications to combinations of psilocybe & cannabis compounds

These were filed by Paul Stamets & CaaMTech

Application by CaaMTech—soon to issue—was “considered to represent the closest prior art”

psilocybinalpha.com/news/patent-co…

5/

An applicant has 30 months from priority date to enter “national phase” with a PCT & begin substantive examination

Deadline is 1/30/22

We are monitoring this & other psilocybin-related applications on @PsilocybinAlpha

Patent Tracker updated here: psilocybinalpha.com/data/psilocybi…

6/6